<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927560</url>
  </required_header>
  <id_info>
    <org_study_id>Robotic First</org_study_id>
    <nct_id>NCT03927560</nct_id>
  </id_info>
  <brief_title>Robotic-Assisted Percutaneous Coronary Intervention</brief_title>
  <official_title>Robotic-Assisted Percutaneous Coronary Intervention - A Safety and Effectiveness Study Applied to the Brazilian Public Health System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percutaneous coronary intervention is a safe procedure. However, its execution is manual,
      fully operator-dependent. The procedure is also associated with radiation exposure to
      patients and physicians. This study will evaluate the robotic assisted percutaneous coronary
      intervention as an alternative to manual operation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 10, 2019</start_date>
  <completion_date type="Anticipated">March 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure Complications</measure>
    <time_frame>1 day</time_frame>
    <description>Death or non-fatal major acute complications on the target vessel (thrombosis, myocardial infarction, perforation or non-planned invasive treatment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>1 day</time_frame>
    <description>Robotic Assisted Procedure Success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence of Major Events</measure>
    <time_frame>1 month</time_frame>
    <description>Death, stent thrombosis, Myocardial Infarction, Stroke</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">83</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Robotic Assisted Percutaneous Coronary Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Robotic Assisted Percutaneous Coronary Intervention</intervention_name>
    <description>Robotic Assisted Percutaneous Coronary Intervention</description>
    <arm_group_label>Robotic Assisted Percutaneous Coronary Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age&gt; = 18 years;

          2. Symptomatic ischemic heart disease and / or objective evidence of myocardial ischemia
             with one or more target lesions;

          3. Elective for percutaneous procedure (i.e. performed in a non-urgent context)

          4. The target lesion (s) must be obstructive, with stenosis diameter &gt; 50% (visual
             analysis);

          5. The interventional planning of all target lesions should include robotic manipulation
             in at least one treatment, as judged by the operator;

          6. Acceptable candidate for myocardial revascularization surgery.

        Exclusion Criteria:

          1. ST-segment elevation myocardial infarction in the last 48 hours before the index
             procedure;

          2. Ejection fraction &lt;30%;

          3. Impaired renal function (creatinine&gt; 2.0 mg / dL) or calculated creatinine clearance
             &lt;30 ml / min;

          4. Platelet count &lt;100,000 cells / mm 3 or&gt; 700,000 cells / mm 3;

          5. Total Leucocytes count &lt;3,000 cells / mm 3;

          6. Suspected or documented active liver disease (including laboratory evidence of
             hepatitis);

          7. Heart transplant recipient;

          8. Allergies known to aspirin, clopidogrel, ticlopidine, ticagrelor, prasugrel, heparin,
             antiproliferative agents of the limus family, or stainless steel;

          9. Patient with a life expectancy of less than 1 month;

         10. Any significant medical condition that in the opinion of the investigator may
             interfere with the patient's ideal participation in this study;

         11. Participation in other research in the last 12 months, unless there may be direct
             benefit to the research subject;

         12. Any invasive cardiac or non-cardiac treatment scheduled within the first month after
             the index procedure.

        Angiographic exclusion criteria

          1. Need for non-robotic (i.e. manual) treatment of another injury in the index procedure
             or in the first month;

          2. Target lesion not accessible by robotic treatment, according to the judgment of the
             operator;

          3. Unprotected coronary artery trunk lesion (stenosis&gt; 50%);

          4. Angiographic thrombus;

          5. Target lesion in surgical graft;

          6. Total occlusion (TIMI 0 or 1 anterograde flow)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pedro Lemos, PhD</last_name>
    <phone>+55 (11) 2151-4306</phone>
    <email>pedro.lemos@einstein.br</email>
  </overall_contact>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>April 29, 2019</last_update_submitted>
  <last_update_submitted_qc>April 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

